The date format must match "dd.mm.YYYY"
New analyses in an addendum confirm hint of an added benefit in one of four research questions. Especially with regard to quality of life, usable data are now available.
In two weeks' time, the 16th HTAi Annual Meeting will start in Cologne: globalization and digitalization also call for adequate methods and effective action in health technology assessment. IQWiG is actively involved.
Meaningful studies are lacking for certain patient groups. Disease-specific registries could help close the data gap.
There are advantages in overall survival, which are not offset by any disadvantages of similar importance. Extent of the added benefit depends on the patient risk scores.
Data are lacking for arguments on the pros and cons, as the available studies examine the outpatient sector. IQWiG proposes a design for a new study.
Symptomatic progression is significantly retarded by this drug. This advantage clearly outweighs the disadvantages presented by some side effects.
In the Journal of Clinical Epidemiology, an international team of authors discusses the possibilities and limitations of graphical representations of statements on absolute effects.
Study indicates longer overall survival of postmenopausal women. However, there is a higher frequency of severe diseases of blood and lymphatic system. Overall, added benefit not proven.
Hint and indication of benefit for primary and secondary wound healing, respectively. But studies still concealed. Comments on preliminary report “primary wound healing” possible until 29.4.
Informative studies are still lacking for the comparison with the currently used risk-based strategy.
The first drug of a new drug class can reduce the number of headache days if other prophylactic medications have failed or have not been an option.
Commissioned by the Federal Ministry of Health, the Institute searched for studies on vaginal (“natural”) birth and assessed them. The guideline group appreciates the high quality of the reports.
Only few study participants received approval-compliant treatment. Therefore, the extent of added benefit is non-quantifiable.
The focus is on international HTA activities. Further topics: 7 years of AMNOG, big data, studies on medical devices, and other topics. Available online at IQWiG as a PDF or as a print version.
This combination showed advantages in survival and recurrence. An added benefit was not proven for another combination used in advanced disease.
From January 2019, Jens Flintrop will be Head of the Communications Unit. After many years as a journal editor, he became press officer at the Westfalen-Lippe Association of SHI Physicians.
Following a negative G-BA decision due to a lack of data in 2013, the drug manufacturer now presented a suitable, albeit very short study.
For psoriasis, it has been known since 2007 that UV light therapy should be combined with brine baths. New data have now shown this also for atopic eczema.
Even eleven years after the first benefit assessment, the evidence base remains inadequate. The hopes to be able to close gaps in knowledge were disappointed when PREFERE failed in 2016 due to a lack of interest.
There are no suitable studies for the benefit assessment of screenings of the general population. Thorough accompanying evaluation is required for hepatitis C screening of risk groups.
+49 221 35685-151
Dr. Anna-Sabine Ernst
+49 221 35685-153
+49 221 35685-158
To save your search result, please copy the link below and paste it into a new tab/window.